ES2561437T3 - Péptidos de CCN3 y análogos de los mismos para uso terapéutico - Google Patents
Péptidos de CCN3 y análogos de los mismos para uso terapéutico Download PDFInfo
- Publication number
- ES2561437T3 ES2561437T3 ES11763563.1T ES11763563T ES2561437T3 ES 2561437 T3 ES2561437 T3 ES 2561437T3 ES 11763563 T ES11763563 T ES 11763563T ES 2561437 T3 ES2561437 T3 ES 2561437T3
- Authority
- ES
- Spain
- Prior art keywords
- ccn3
- ccn3p38
- substituted
- human
- ccn2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108700024729 Nephroblastoma Overexpressed Proteins 0.000 title claims abstract description 103
- 102000047330 Nephroblastoma Overexpressed Human genes 0.000 title description 77
- 230000001225 therapeutic effect Effects 0.000 title description 6
- 241000282414 Homo sapiens Species 0.000 claims abstract description 53
- 235000018417 cysteine Nutrition 0.000 claims abstract description 26
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 47
- 230000004761 fibrosis Effects 0.000 claims description 47
- 150000001413 amino acids Chemical group 0.000 claims description 25
- 235000001014 amino acid Nutrition 0.000 claims description 23
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 150000001945 cysteines Chemical class 0.000 claims 12
- -1 cysteine amino acids Chemical group 0.000 claims 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 115
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 115
- 108090000765 processed proteins & peptides Proteins 0.000 description 62
- 210000004027 cell Anatomy 0.000 description 58
- 101150036984 CCN3 gene Proteins 0.000 description 50
- 230000000694 effects Effects 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 41
- 102000004196 processed proteins & peptides Human genes 0.000 description 39
- 235000018102 proteins Nutrition 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 102000008186 Collagen Human genes 0.000 description 23
- 108010035532 Collagen Proteins 0.000 description 23
- 229920001436 collagen Polymers 0.000 description 23
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 20
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 20
- 210000002744 extracellular matrix Anatomy 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 15
- 238000009825 accumulation Methods 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 12
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000007170 pathology Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 10
- 102000039854 CCN family Human genes 0.000 description 9
- 108091068251 CCN family Proteins 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 102000012422 Collagen Type I Human genes 0.000 description 8
- 108010022452 Collagen Type I Proteins 0.000 description 8
- 101000777555 Homo sapiens CCN family member 3 Proteins 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 208000034189 Sclerosis Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 208000017169 kidney disease Diseases 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 235000004400 serine Nutrition 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 230000003510 anti-fibrotic effect Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 208000033679 diabetic kidney disease Diseases 0.000 description 6
- 230000003176 fibrotic effect Effects 0.000 description 6
- 210000003584 mesangial cell Anatomy 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 201000002793 renal fibrosis Diseases 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000037390 scarring Effects 0.000 description 6
- 102100031171 CCN family member 1 Human genes 0.000 description 5
- 102100031170 CCN family member 3 Human genes 0.000 description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 5
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 208000020832 chronic kidney disease Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102100036537 von Willebrand factor Human genes 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 101150042405 CCN1 gene Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000003831 deregulation Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108010047303 von Willebrand Factor Proteins 0.000 description 4
- 229960001134 von willebrand factor Drugs 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- 102100031173 CCN family member 4 Human genes 0.000 description 3
- 101710137353 CCN family member 4 Proteins 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 101100219984 Mus musculus Ccn3 gene Proteins 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 102000002938 Thrombospondin Human genes 0.000 description 3
- 108060008245 Thrombospondin Proteins 0.000 description 3
- 102100036034 Thrombospondin-1 Human genes 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003630 growth substance Substances 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 3
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 3
- 230000002206 pro-fibrotic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 206010001488 Aggression Diseases 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100025215 CCN family member 5 Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 2
- 101100219983 Homo sapiens CCN3 gene Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000005475 Vascular calcification Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000002227 vasoactive effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 101710137354 CCN family member 5 Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 description 1
- 101100264044 Caenorhabditis elegans cwn-2 gene Proteins 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 101150091877 Ccn2 gene Proteins 0.000 description 1
- 102100025175 Cellular communication network factor 6 Human genes 0.000 description 1
- 102000000018 Chemokine CCL2 Human genes 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010056533 Congenital hepatic fibrosis Diseases 0.000 description 1
- 101100373143 Drosophila melanogaster Wnt5 gene Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000777560 Homo sapiens CCN family member 4 Proteins 0.000 description 1
- 101000934220 Homo sapiens CCN family member 5 Proteins 0.000 description 1
- 101000934310 Homo sapiens Cellular communication network factor 6 Proteins 0.000 description 1
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 1
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 1
- 102100020781 Insulin-like growth factor-binding protein-like 1 Human genes 0.000 description 1
- 101710203697 Insulin-like growth factor-binding protein-like 1 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100219978 Mus musculus Ccn2 gene Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102100037599 SPARC Human genes 0.000 description 1
- 206010050207 Skin fibrosis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101100219979 Sus scrofa CCN2 gene Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 101150019524 WNT2 gene Proteins 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 108700020987 Wnt-1 Proteins 0.000 description 1
- 102000052547 Wnt-1 Human genes 0.000 description 1
- 108700020986 Wnt-2 Proteins 0.000 description 1
- 102000052556 Wnt-2 Human genes 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 108700020985 Wnt-3 Proteins 0.000 description 1
- 101000777551 Xenopus laevis CCN family member 3 Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000035824 beta Subunit Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010081485 beta Subunit Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000014581 connective tissue growth factor production Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000047612 human CCN2 Human genes 0.000 description 1
- 102000047605 human CCN3 Human genes 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000014861 isolated congenital hepatic fibrosis Diseases 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000003245 peritoneal mesothelial cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 201000006038 polycystic kidney disease 4 Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34169410P | 2010-04-02 | 2010-04-02 | |
| US341694P | 2010-04-02 | ||
| PCT/US2011/031121 WO2011123858A2 (en) | 2010-04-02 | 2011-04-04 | Ccn3 peptides and analogs thereof for therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2561437T3 true ES2561437T3 (es) | 2016-02-26 |
Family
ID=44712870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11763563.1T Active ES2561437T3 (es) | 2010-04-02 | 2011-04-04 | Péptidos de CCN3 y análogos de los mismos para uso terapéutico |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8518395B2 (enExample) |
| EP (1) | EP2552462B1 (enExample) |
| JP (1) | JP5939584B2 (enExample) |
| CN (1) | CN102947326B (enExample) |
| DK (1) | DK2552462T3 (enExample) |
| ES (1) | ES2561437T3 (enExample) |
| WO (1) | WO2011123858A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9114112B2 (en) * | 2010-04-02 | 2015-08-25 | Rosalind Franklin University Of Medicine And Science | CCN3 and CCN3 peptides and analogs thereof for therapeutic uses |
| CN104749371B (zh) * | 2013-12-30 | 2016-09-28 | 神州细胞工程有限公司 | 人肾母细胞瘤过度表达基因编码蛋白酶联免疫试剂盒 |
| KR101576904B1 (ko) * | 2014-07-31 | 2015-12-14 | (주)케어젠 | 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도 |
| US10028906B2 (en) * | 2016-03-22 | 2018-07-24 | Rosalind Franklin University Of Medicine And Science | Method and kit for treating a solid tumor and associated desmoplasia |
| CN108795867A (zh) * | 2018-06-05 | 2018-11-13 | 华东理工大学 | 用于构建结肠癌细胞腹膜转移体外三维模型的方法 |
| EP3711772A1 (en) * | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
| CN115433776B (zh) * | 2022-09-30 | 2023-12-22 | 中国医学科学院阜外医院 | Ccn3在调控血管平滑肌细胞钙化中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE485834T1 (de) | 1998-09-08 | 2010-11-15 | Ford Henry Health System | Verfahren zum nachweis von bindegewebswachstumsfaktor zur diagnose von nierkrankheiten |
| US20030059768A1 (en) | 2000-02-25 | 2003-03-27 | Corine Vernet | Novel polypeptides and nucleic acids encoding same |
| US20040009940A1 (en) | 2000-10-20 | 2004-01-15 | Coleman Michael E. | Gene delivery formulations and methods for treatment of ischemic conditions |
| FR2825928B1 (fr) | 2001-06-18 | 2004-04-02 | Ecole Norm Superieure Cachan | Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine |
| EP1382347A1 (en) | 2002-07-17 | 2004-01-21 | UNIVERSITE PARIS 7 - Denis DIDEROT | Use of CCN protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux |
| EP1608970A4 (en) | 2003-03-31 | 2006-06-14 | Munin Corp | CCN3 COMPOSITIONS AND METHODS |
| FR2858234B1 (fr) * | 2003-08-01 | 2007-09-14 | Centre Nat Rech Scient | Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers |
| CA2582224A1 (en) * | 2004-09-28 | 2006-04-06 | Lester F. Lau | Compositions and methods for modulating tissue regeneration and chemotactic responses |
| DK1841316T3 (da) * | 2005-01-10 | 2011-08-08 | Univ Rosalind Franklin Medicine & Science | CCN3-protein til anvendelse ved behandling og diagnose af nyresygdomme |
| US7780949B2 (en) * | 2005-01-10 | 2010-08-24 | Rosalind Franklin University Of Medicine And Science | Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases |
| GB0618748D0 (en) * | 2006-09-22 | 2006-11-01 | Univ Belfast | Peptide |
-
2011
- 2011-04-04 CN CN201180026057.3A patent/CN102947326B/zh not_active Expired - Fee Related
- 2011-04-04 WO PCT/US2011/031121 patent/WO2011123858A2/en not_active Ceased
- 2011-04-04 JP JP2013502918A patent/JP5939584B2/ja not_active Expired - Fee Related
- 2011-04-04 US US13/079,693 patent/US8518395B2/en active Active
- 2011-04-04 DK DK11763563.1T patent/DK2552462T3/en active
- 2011-04-04 ES ES11763563.1T patent/ES2561437T3/es active Active
- 2011-04-04 EP EP11763563.1A patent/EP2552462B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| US20110250180A1 (en) | 2011-10-13 |
| WO2011123858A2 (en) | 2011-10-06 |
| JP2013523778A (ja) | 2013-06-17 |
| CN102947326A (zh) | 2013-02-27 |
| EP2552462A4 (en) | 2013-12-18 |
| JP5939584B2 (ja) | 2016-06-22 |
| EP2552462B1 (en) | 2015-12-16 |
| EP2552462A2 (en) | 2013-02-06 |
| CN102947326B (zh) | 2016-02-10 |
| DK2552462T3 (en) | 2016-02-08 |
| US8518395B2 (en) | 2013-08-27 |
| WO2011123858A3 (en) | 2011-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2561437T3 (es) | Péptidos de CCN3 y análogos de los mismos para uso terapéutico | |
| US12024544B2 (en) | CCN3 and CCN3 peptides and analogs thereof for therapeutic use | |
| Chien et al. | Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis | |
| JP2007051150A (ja) | 結合組織増殖因子 | |
| US20150087597A1 (en) | Polypeptides and methods of use | |
| PT98805B (pt) | Processo de preparacao de uma nova proteina de ligacao ao factor de crescimento semelhante a insulina (igfbp-4) | |
| JP2011231113A (ja) | 新規抗血管新生剤及びその使用、特には癌の治療における使用 | |
| PT2497780E (pt) | Compostos relacionados com tdf e seus análogos | |
| PT98804B (pt) | Processo de preparacao de igfbp-4 ou um fragmento da mesma | |
| US7780949B2 (en) | Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases | |
| ES2395260T3 (es) | Proteína CCN3 para su utilización en el tratamiento y el diagnóstico de enfermedades renales | |
| JP2008013436A (ja) | 血管形成促進剤 | |
| WO1999055361A1 (en) | Neovascularization inhibitors | |
| JP6134146B2 (ja) | ヒトアメロゲニン部分ペプチド | |
| ES2245048T3 (es) | Factor de crecimiento derivado de cadherina y su uso. | |
| Bogatkevich et al. | Scleroderma lung fibroblasts: contractility and connective tissue growth factor | |
| WO2013166944A1 (zh) | 一种rtn4b相关多肽及其制备与应用 |